BioAtla IPO Presentation Deck

BA3021 ROR2-ADC Phase 2 Clinical Program Potentially Registration-Enabling Phase 2 Trials (RP2D: 1.8mg/kg Q2W) Timeline Phase 2 Program- NSCLC mono & combination w PD-1 ROR2 Positive: PD1-refractory n=200 Phase 2 Program-melanoma mono & combination w PD-1 ROR2 Positive; PD1-refractory n=200 1 NSCLC: Prior disease progression on PD- 1/L1 inhibitor Interim analysis n=20 Primary endpoint: ORR Population matched synthetic arm Note: Ovarian IIT not shown Phase 2 population Data read-out Melanoma: Prior disease progression on PD- 1/L1 inhibitor bicatla 20

View entire presentation